Evotec SE (EVO)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Evotec SE (EVO)
Company Performance

Current Price

as of Dec 03, 2024

$4.54

P/E Ratio

N/A

Market Cap

$1.6B

Description

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Metrics

Overview

  • HQHamburg, HA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerEVO
  • Price$4.54-3.81%

Trading Information

  • Market cap$1.60B
  • Float78.12%
  • Average Daily Volume (1m)363,066
  • Average Daily Volume (3m)200,499
  • EPS-$0.52

Company

  • Revenue$842.21M
  • Rev growth (1yr)-4.87%
  • Net income-$43.54M
  • Gross margin9.89%
  • EBITDA marginN/A
  • EBITDAN/A
  • EV$1.48B
  • EV/Revenue1.76
  • P/EN/A
  • P/S1.91
  • P/B1.49